Claims
- 1. A growth hormone releasing composition consisting essentially of human growth hormone releasing factor (GRF) and a stability enhancing amount of a stabilizing agent selected from the group consisting of human serum albumin or glycine wherein said GRF has the amino acid sequence
- H--Tyr--Ala--Asp--Ala--Ile--Phe--Thr--Asn--Ser--Tyr--Arg--Lys--Val--Leu--Gly--Gln--Leu--Ser--Ala--Arg--Lys--Leu--Leu--Gln--Asp--Ile--Met--Ser--Arg--Gln--Gln--Gly--Glu--Ser--Asn--Gln--Glu--Arg--Gly--Ala--Arg--Ala--Arg--Leu--NH.sub.2 or the amino acid sequence
- H--Tyr--Ala--Asp--Ala--Ile--Phe--Thr--Asn--Ser--Tyr--Arg--Lys--Val--Leu--Gly--Gln--Leu--Ser--Ala--Arg--Lys--Leu--Leu--Gln--Asp--Iln--Met--Ser--Arg--NH.sub.2.
- 2. A composition as in claim 1 further comprising a buffer selected from the group consisting of acetate, citrate and phosphate buffers wherein the amount of said buffer is an amount sufficient to maintain the pH of the composition at pH 2 to 6.
- 3. A composition as in claim 1 wherein the amount of glycine or human serum albumin comprises 100 micrograms to 30 milligrams, per 100 micrograms of growth hormone releasing factor.
- 4. A composition as in claim 1 wherein said composition is lyophilized.
- 5. A composition as in claim 4 wherein said composition is maintained under a nitrogen gas atmosphere.
- 6. A composition as in claim 1 further comprising one of the group consisting of a pharmaceutically acceptable carrier, an isotonizer and a soothing agent.
- 7. A process enhancing the stability of a growth hormone releasing factor (GRF) composition consisting essentially of adding a stability enhancing amount of a stabilizing agent selected from the group consisting of human serum albumin and glycine to GRF wherein said GRF has the amino acid sequence
- H--Tyr--Ala--Asp--Ala--Ile--Phe--Thr--Asn--Ser--Tyr--Arg--Lys--Val--Leu--Gly--Gln--Leu--Ser--Ala--Arg--Lys--Leu--Leu--Gln--Asp--Ile--Met--Ser--Arg--Gln--Gln--Gly--Glu--Ser--Asn--Gln--Glu--Arg--Gly--Ala--Arg--Ala--Arg--Leu--NH.sub.2 or the amino acid sequence
- H--Tyr--Ala--Asp--Ala--Ile--Phe--Thr--Asn--Ser--Tyr--Arg--Lys--Val--Leu--Gly--Gln--Leu--Ser--Ala--Arg--Lys--Leu--Leu--Gln--Asp--Ile--Met--Ser--Arg--NH.sub.2.
- 8. A process as in claim 7 further comprising a buffer selected from the group consisting of acetate, citrate and phosphate buffers wherein the amount of said buffer is an amount sufficient to maintain the pH of the composition at pH 2 to 6.
- 9. A process in claim 7 wherein the amount of glycine or human serum comprises 100 micrograms to 30 milligrams per 100 micrograms of growth hormone releasing factor.
- 10. A process as in claim 7 wherein said composition is lyophilized.
- 11. A process as in claim 10 wherein said composition is maintained under a nitrogen gas atmosphere.
- 12. A process as in claim 7 further comprising one of the group consisting of a pharmaceutically acceptable carrier, an isotonize and a soothing agent.
Priority Claims (2)
Number |
Date |
Country |
Kind |
59-280036 |
Dec 1984 |
JPX |
|
60-207244 |
Sep 1985 |
JPX |
|
Parent Case Info
This is a continuation of co-pending application Ser. No. 813,013, filed on Dec. 24, 1985, now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (2)
Entry |
Ling et al., PNAS USA, vol. 81 (1984), pp. 4302-4306. |
Seifert et al., Nature, vol. 313 (1985), pp. 487-489. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
813013 |
Dec 1985 |
|